Showing 1 of 1 PublicationsTherapeutic Targeting of RAS Mutant CancersStites E, Paskvan K, Kato S. Therapeutic Targeting of RAS Mutant Cancers. 2022 DOI: 10.1017/9781009064828.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSingle nucleotide variantsGlycine to cysteineRas GTPasesNucleotide variantsRAS-targeted therapiesCysteine residuesHuman cancersOncogenic mutationsMutationsRasOncogeneCysteineCovalent inhibitorsKRAS oncogeneGTPaseFDA approvalTargeting KRASKRASCodonDownload Full List
Therapeutic Targeting of RAS Mutant CancersStites E, Paskvan K, Kato S. Therapeutic Targeting of RAS Mutant Cancers. 2022 DOI: 10.1017/9781009064828.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSingle nucleotide variantsGlycine to cysteineRas GTPasesNucleotide variantsRAS-targeted therapiesCysteine residuesHuman cancersOncogenic mutationsMutationsRasOncogeneCysteineCovalent inhibitorsKRAS oncogeneGTPaseFDA approvalTargeting KRASKRASCodon